1
Three years after its first launch in the US, there are signs that Biogen and Eisai’s Alzheimer’s disease Leqembi therapy is finally gathering some momentum commercially.
In its fourth-quarter results update, Biogen said global sales of the anti-amyloid antibody climbed 54% to $134 million, including some $78 million from the US market, which helped the company partially offset a steep decline in its multiple sclerosis franchise revenues.
The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection version of the drug that can be…